Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) FCF Margin (2016 - 2025)

Historic FCF Margin for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to 16.66%.

  • Ani Pharmaceuticals' FCF Margin rose 114900.0% to 16.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 18.83%, marking a year-over-year increase of 50100.0%. This contributed to the annual value of 7.78% for FY2024, which is 148400.0% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its FCF Margin stood at 16.66% for Q3 2025, which was up 114900.0% from 33.97% recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' FCF Margin registered a high of 178.3% during Q1 2021, and its lowest value of 32.4% during Q1 2022.
  • Its 5-year average for FCF Margin is 14.52%, with a median of 9.39% in 2024.
  • In the last 5 years, Ani Pharmaceuticals' FCF Margin skyrocketed by 1779600bps in 2021 and then plummeted by -2107000bps in 2022.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' FCF Margin stood at 20.58% in 2021, then skyrocketed by 61bps to 8.0% in 2022, then skyrocketed by 503bps to 32.25% in 2023, then plummeted by -78bps to 7.07% in 2024, then surged by 136bps to 16.66% in 2025.
  • Its FCF Margin was 16.66% in Q3 2025, compared to 33.97% in Q2 2025 and 16.5% in Q1 2025.